Press Releases - Genentech
WEBDec 6, 2010 · Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation. 21 Nov 2023. Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development. 26 Oct 2023.
Genentech to close cancer immunology research department - Fierce Biotech
WEBAug 16, 2024 · Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months.
Genentech, a biotech with a storied past, confronts new ... - STAT
WEB6 days ago · By Jonathan Wosen. Sept. 16, 2024. West Coast Biotech & Life Sciences Reporter. For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise ...
FDA Grants Breakthrough Therapy Designation to Genentech’s …
WEBMay 21, 2024 · Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and...
Genentech: Press Releases | Tuesday, May 28, 2024
WEBMay 28, 2024 · FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation. Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options.
Roche’s Genentech returns Alzheimer’s assets to AC Immune
WEBJan 22, 2024 · Genentech is walking away from an 18-year relationship with AC Immune, handing back global rights to a pair of Alzheimer’s disease drug candidates after suffering a series of setbacks in the...
Genentech: Press Releases | Tuesday, Nov 21, 2023
WEBNov 21, 2023 · Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities ...
Genentech, Sangamo ink Alzheimer’s deal | Nature Biotechnology
WEBSep 13, 2024 · Genentech, part of Roche, has signed an exclusive license with Sangamo Therapeutics to develop genomic treatments for two neurodegenerative diseases. Sangamo will receive $50 million up front and ...
Genentech and NVIDIA Enter Into Strategic AI Research …
WEBNov 21, 2023 · SOUTH SAN FRANCISCO, Calif., November 21, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that...
Nvidia Looks to Genentech for Its Next Leap in AI Drug Discovery
WEBNov 28, 2023 · Nvidia has expanded in artificial intelligence (AI)-based life sciences through a new AI drug discovery collaboration with Roche’s Genentech subsidiary.
Skip to content